Fig. 2From: Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapyOverall survival time compared in patients with documented hepatic metastases versus patients without hepatic metastasisBack to article page